Manoguerra Anthony S, Erdman Andrew R, Woolf Alan D, Chyka Peter A, Caravati E Martin, Scharman Elizabeth J, Booze Lisa L, Christianson Gwenn, Nelson Lewis S, Cobaugh Daniel J, Troutman William G
American Association of Poison Control Centers, Washington, District of Columbia 20016, USA.
Clin Toxicol (Phila). 2008 Aug;46(7):661-76. doi: 10.1080/15563650802178136.
A review of US poison center data for 2004 showed over 9000 ingestions of valproic acid. A guideline that determines the conditions for emergency department referral and prehospital care could potentially optimize patient outcome, avoid unnecessary emergency department visits, reduce health care costs, and reduce life disruption for patients and caregivers. An evidence-based expert consensus process was used to create the guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the lead author. The entire panel discussed and refined the guideline before distribution to secondary reviewers for comment. The panel then made changes based on the secondary review comments. The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected ingestion of valproic acid by 1) describing the process by which an ingestion of valproic acid might be managed, 2) identifying the key decision elements in managing cases of valproic acid ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to the acute ingestion and acute-on-chronic ingestion of immediate-release and extended-release dosage forms of valproic acid, divalproex, and valproate sodium alone. Co-ingestion of additional substances could require different referral and management recommendations depending on the combined toxicities of the substances. This review focuses on the ingestion of more than a single therapeutic dose and the effects of an overdose. Although therapeutic doses of valproic acid can cause adverse effects in adults and children, some idiosyncratic and some dose-dependent, these cases are not considered. This guideline is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions might be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. This guideline does not substitute for clinical judgment. Recommendations are in chronological order of likely clinical use. The grade of recommendation is in parentheses. 1) All patients with suicidal intent, intentional abuse, or in whom a malicious intent is suspected (e.g., child abuse or neglect) should be referred to an emergency department (Grade D). 2) Patients who are symptomatic (more than somnolence or exhibiting coma or seizures) after a valproic acid ingestion should be referred to an emergency department (Grade C). 3) Asymptomatic patients with an unintentional acute ingestion of 50 mg/kg or more or asymptomatic patients who are taking the drug therapeutically and who take an additional single acute ingestion of 50 mg/kg or more of any valproic acid formulation should be referred to an emergency department for evaluation (Grade C). 4) Patients with unintentional ingestions of immediate-release valproic acid formulations, who are asymptomatic, and more than 6 hours has elapsed since the time of ingestion, can be observed at home (Grade C). 5) Patients with unintentional ingestions of delayed-release or extended-release formulations of valproic acid who are asymptomatic, and more than 12 hours has elapsed since the time of ingestion, can be observed at home (Grade C). 6) Pregnant women who ingest below the dose for emergency department referral and do not have other referral conditions should be directed to their primary care obstetrical provider for evaluation of potential maternal and fetal risk. Routine referral to an emergency department for immediate care is not required (Grade D). 7) Do not induce emesis (Grade C). 8) Activated charcoal can be administered to asymptomatic patients who have ingested valproic acid within the preceding hour (Grade C). Prehospital activated charcoal administration, if available, should only be carried out by health professionals and only if no contraindications are present. Poison centers should follow local protocols and experience with its use. Do not delay transportation in order to administer activated charcoal (Grades D). 9) In patients who have ingested valproic acid and who are comatose, naloxone can be considered for prehospital administration in the doses used for treatment of opioid overdose, particularly if the patient has respiratory depression (Grade C). 10) A benzodiazepine can be administered by EMS personnel if convulsions are present and if authorized by EMS medical direction, expressed by written treatment protocol or policy, or if there is direct medical oversight (Grade C).
对美国毒物控制中心2004年数据的回顾显示,丙戊酸的摄入案例超过9000例。制定一项确定急诊科转诊条件和院前护理条件的指南,有可能优化患者的治疗结果,避免不必要的急诊科就诊,降低医疗成本,并减少患者及其护理人员的生活干扰。采用了基于证据的专家共识流程来制定该指南。相关文章由一名经过培训的内科医生研究员提取摘要。指南初稿由第一作者撰写。在分发给二级评审人员征求意见之前,整个小组对指南进行了讨论和完善。然后,小组根据二级评审意见进行了修改。本指南的目的是通过以下方式协助毒物控制中心人员对疑似摄入丙戊酸的患者进行适当的院外分诊和初始院外管理:1)描述管理丙戊酸摄入的过程;2)确定管理丙戊酸摄入病例的关键决策要素;3)提供反映当前知识水平的清晰实用的建议;4)确定研究需求。本指南仅适用于单独急性摄入和急性-on-慢性摄入速释和缓释剂型的丙戊酸、双丙戊酸钠和丙戊酸钠。同时摄入其他物质可能需要根据这些物质的联合毒性提出不同的转诊和管理建议。本综述重点关注超过单一治疗剂量的摄入以及过量摄入的影响。虽然丙戊酸的治疗剂量可在成人和儿童中引起不良反应,有些是特异质性的,有些是剂量依赖性的,但这些情况不在本指南考虑范围内。本指南基于对当前科学和临床信息的评估。专家共识小组认识到,具体的患者护理决策可能与本指南不一致,在考虑所有相关情况后,这是患者和提供护理的卫生专业人员的特权。本指南不能替代临床判断。建议按照可能的临床使用时间顺序排列。推荐等级在括号内。1)所有有自杀意图、故意滥用或被怀疑有恶意意图(如虐待或忽视儿童)的患者应转诊至急诊科(D级)。2)丙戊酸摄入后出现症状(不仅仅是嗜睡或昏迷或癫痫发作)的患者应转诊至急诊科(C级)。3)无意急性摄入50mg/kg或更多丙戊酸的无症状患者,或正在接受该药物治疗且额外单次急性摄入任何丙戊酸制剂50mg/kg或更多的无症状患者,应转诊至急诊科进行评估(C级)。4)无意摄入速释丙戊酸制剂且无症状、摄入时间已超过6小时的患者,可以在家中观察(C级)。5)无意摄入丙戊酸缓释或长效制剂且无症状、摄入时间已超过12小时的患者,可以在家中观察(C级)。6)摄入剂量低于急诊科转诊剂量且无其他转诊条件的孕妇,应转至其初级保健产科医生处,以评估潜在的母婴风险。无需常规转诊至急诊科进行即时护理(D级)。7)不要诱导呕吐(C级)。8)对于在过去一小时内摄入丙戊酸的无症状患者,可以给予活性炭(C级)。如果有条件,院前活性炭给药仅应由卫生专业人员进行,且仅在无禁忌证的情况下进行。毒物控制中心应遵循当地的操作规程和使用经验。不要为了给予活性炭而延迟运输(D级)。9)对于摄入丙戊酸且昏迷的患者,如果有呼吸抑制,可考虑在院前给予用于治疗阿片类药物过量的剂量的纳洛酮(C级)。10)如果出现惊厥且经急救医疗服务(EMS)医疗指导授权(以书面治疗方案或政策表示)或有直接医疗监督,EMS人员可以给予苯二氮䓬类药物(C级)。